Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-controlled phase II trial.
Frederik Marme
Honoraria - Sanofi
Research Funding - Bayer
Other Remuneration - Sanofi
Bernd Gerber
No relevant relationships to disclose
Marcus Schmidt
No relevant relationships to disclose
Volker Jochen Moebus
No relevant relationships to disclose
Frank Gerhard Foerster
No relevant relationships to disclose
Eva-Maria Grischke
No relevant relationships to disclose
Matthias W. Beckmann
No relevant relationships to disclose
Dirk Strumberg
No relevant relationships to disclose
Erich Solomayer
No relevant relationships to disclose
Peter Klare
No relevant relationships to disclose
Christiane Windemuth-Kieselbach
No relevant relationships to disclose
Andreas Schneeweiss
Consultant or Advisory Role - Celgene; Medac; Roche
Honoraria - AstraZeneca; Celgene; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - Celgene; Roche